BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24601650)

  • 21. Design and synthesis of quinazolinone tagged acridones as cytotoxic agents and their effects on EGFR tyrosine kinase.
    Babu YR; Bhagavanraju M; Reddy GD; Peters GJ; Prasad VV
    Arch Pharm (Weinheim); 2014 Sep; 347(9):624-34. PubMed ID: 24866341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, molecular docking and antitumor activity of novel pyrrolizines with potential as EGFR-TK inhibitors.
    Belal A
    Bioorg Chem; 2015 Apr; 59():124-9. PubMed ID: 25748126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.
    Liu B; Fu L; Zhang C; Zhang L; Zhang Y; Ouyang L; He G; Huang J
    Oncotarget; 2015 Mar; 6(9):6762-75. PubMed ID: 25742792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
    Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
    Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies.
    Koh EJ; El-Gamal MI; Oh CH; Lee SH; Sim T; Kim G; Choi HS; Hong JH; Lee SG; Yoo KH
    Eur J Med Chem; 2013; 70():10-21. PubMed ID: 24128410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
    Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
    Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents.
    Liu K; Lu X; Zhang HJ; Sun J; Zhu HL
    Eur J Med Chem; 2012 Jan; 47(1):473-8. PubMed ID: 22119130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and molecular docking studies of 2-(furan-2-yl)quinazolin-4-one derivatives as potential antiproliferative agents.
    Ahmed MF; Belal A
    Arch Pharm (Weinheim); 2015 Jul; 348(7):487-97. PubMed ID: 25921702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
    El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
    Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 4-Substituted-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, antitumor and EGFR tyrosine kinase inhibitory activity.
    Abbas SE; Aly EI; Awadallah FM; Mahmoud WR
    Chem Biol Drug Des; 2015 May; 85(5):608-22. PubMed ID: 25318985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.
    Abdelatef SA; El-Saadi MT; Amin NH; Abdelazeem AH; Omar HA; Abdellatif KRA
    Eur J Med Chem; 2018 Apr; 150():567-578. PubMed ID: 29549841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
    Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, anti-breast cancer activity, and molecular modeling of some benzothiazole and benzoxazole derivatives.
    Abdelgawad MA; Belal A; Omar HA; Hegazy L; Rateb ME
    Arch Pharm (Weinheim); 2013 Jul; 346(7):534-41. PubMed ID: 23740859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors.
    Abd El Hadi SR; Lasheen DS; Hassan MA; Abouzid KA
    Arch Pharm (Weinheim); 2016 Nov; 349(11):827-847. PubMed ID: 27734525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
    Ibrahim DA; Abou El Ella DA; El-Motwally AM; Aly RM
    Eur J Med Chem; 2015 Sep; 102():115-31. PubMed ID: 26256032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and molecular docking of α,β-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity.
    Xu YY; Cao Y; Ma H; Li HQ; Ao GZ
    Bioorg Med Chem; 2013 Jan; 21(2):388-94. PubMed ID: 23245570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).
    Chan S; Han K; Qu R; Tong L; Li Y; Zhang Z; Cheng H; Lu X; Patterson A; Smaill J; Ren X; Ding J; Xie H; Ding K
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4277-81. PubMed ID: 26259806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
    Cheng W; Yuan Y; Qiu N; Peng P; Sheng R; Hu Y
    Bioorg Med Chem; 2014 Dec; 22(24):6796-805. PubMed ID: 25468044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.